Effects of Glucagon-Like Peptide-1 Receptor Agonists on Upper Gastrointestinal Endoscopy: A Meta-Analysis

• Published in: Clinical gastroenterology and hepatology Vol. 23; no. 5; pp. 715 - 725.e3
• Main Authors: Facciorusso, Antonio, Ramai, Daryl, Dhar, Jahnvi, Samanta, Jayanta, Chandan, Saurabh, Gkolfakis, Paraskevas, Crinò, Stefano Francesco, Maida, Marcello, Anderloni, Andrea, Boskoski, Ivo, Triantafyllou, Konstantinos, Dinis-Ribeiro, Mario, Hassan, Cesare, Fuccio, Lorenzo, Arvanitakis, Marianna
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2025
• Subjects: Adverse Event; Aspiration; Complication; Diabetes; Endoscopy, Gastrointestinal; Gastroenterology and Hepatology; Gastrointestinal Contents - drug effects; Gastroscopy; Glucagon-Like Peptide-1 Receptor Agonists - administration & dosage; Glucagon-Like Peptide-1 Receptor Agonists - adverse effects; Humans; T2DM; OR; AE; Aspiration; CI; Gastroscopy; Adverse Event; ASA; RGC; Complication; GLP-1RA; Diabetes; AGA; BMI; body mass index; American Society of Anesthesiologists; odds ratio; retained gastric content; glucagon-like peptide-1 receptor agonist; type 2 diabetes mellitus; confidence interval; American Gastroenterological Association
• ISSN: 1542-3565; 1542-7714; 1542-7714
• DOI: 10.1016/j.cgh.2024.07.021

Limited evidence exists regarding the impact of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on upper endoscopy. Therefore, a meta-analysis was conducted to comprehensively review the available evidence on this subject. A systematic bibliographic search was carried out until May 2024. Pooled estimates were analyzed using a random-effects model, with results presented as odds ratio (OR) and 95% confidence interval (CI). The primary outcome assessed was the rate of retained gastric content (RGC), while secondary outcomes included rates of aborted and repeated procedures, adverse event rate, and rates of aspiration. This analysis included 13 studies involving a total of 84,065 patients. Patients receiving GLP-1RA therapy exhibited significantly higher rates of RGC (OR, 5.56; 95% CI, 3.35 to 9.23), a trend that was consistent among patients with diabetes (OR, 2.60; 95% CI, 2.23 to 3.02). Adjusted analysis, accounting for variables such as sex, age, body mass index, diabetes, and other therapies, confirmed the elevated rates of RGC in the GLP-1RA user group (adjusted OR, 4.20; 95% CI, 3.42 to 5.15). Furthermore, rates of aborted and repeated procedures were higher in the GLP-1RA user group (OR, 5.13; 95% CI, 3.01 to 8.75; and OR, 2.19; 95% CI, 1.43 to 3.35; respectively). However, no significant differences were found in AE and aspiration rates between the 2 groups (OR, 4.04; 95% CI, 0.63 to 26.03; and OR, 1.75; 95% CI, 0.64 to 4.77; respectively). Use of GLP-1RAs is associated with increased retention of gastric contents and more frequent aborted procedures during upper endoscopy. However, the adverse event and aspiration rates do not seem different; therefore, adjusting fasting time instead of routinely withholding GLP-1RAs could be reasonable in these patients. [Display omitted]